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INTRODUCTION 
Virus neutralisation assays detect and quantify neutralising antibody responses raised 
against the envelope glycoproteins of many pathogenic viruses, enabling vaccine 
evaluation and serosurveillance studies to take place. However, the necessity to 
perform these assays in biosafety level (BSL-) 3 or 4 laboratories, and the expensive 
associated personnel and equipment costs of such precautions, inhibits the broad 
application of such assays, especially for laboratories with poor funding or resources. 
 
Pseudotype viruses (PVs) are a potential solution to this dilemma.  PVs are chimeric, 
replication-deficient virions, often comprised of a retroviral core harbouring a reporter 
gene, combined with heterologous envelope glycoproteins, which mimic the binding 
and entry mechanisms of their wild-type counterparts. Successful transduction of a 
permissible cell line results in reporter gene integration and expression, which can be 
quantified as a measure of PV infectivity. They can therefore be safely employed in 
pseudotype virus neutralisation assays (PVNAs), bypassing high biosafety requirements 
and performing comparably with established serological assays[1-2].  
 
Selection of ‘cheap’ reporter genes such as β-galactosidase or secreted alkaline 
phosphatase (SEAP)[3], low serum sample requirements (<5µl) and multiplexing all 
reduce the cost-per-assay burden of the PVNA platform[2]. Despite this, the current 
necessity to maintain dry-ice transportation and cold-chain storage of PV supernatant 
presents a serious financial obstacle for global distribution of PVNA-based kits.  
 
AIM  
To assess the viability of PV lyophilisation with a view to producing, transporting and 
using a PVNA-based serological kit. Pseudotype infectivity was calculated after 
lyophilisation[4] and immediate reconstitution, as well as incubating freeze-dried pellets 
at a variety of temperatures and humidities before use. Integrity of glycoprotein 
structure was also examined by employing reconstituted PVs in downstream 
neutralisation assays.  
 















Figure 1: Schematic of the 3-plasmid co-transfection system of PV production for use 
in neutralisation assays[5] 
 
Generation of pseudotype viruses 
Influenza H5 A/Vietnam/1194/2004, rabies (RABV) Evelyn Rokitniki Abseleth (ERA) and 
Marburg (MARV) Lake Victoria strains were produced by transfection (Fugene6, 
Promega) of plasmids encoding HIV gag-pol (p8.91), firefly luciferase (pCSFLW) and 
either influenza HA, rabies G or Marburg GP proteins (pI.18-HA, pI.18-G or pCAGGS-GP) 
into HEK293T/17 producer cells. For H5 PV production, exogenous recombinant 
neuraminidase from Clostridium perfringens (Sigma) was added 24 hours after 
transfection. Viral supernatants were harvested at 48 hours post-transfection, passed 
through a 0.45µm-pore filter  and stored at -80°C[1-2].  
 
Freeze-drying treatment of pseudotype viruses (Figures 2 & 3) 
Lyophilisation of pseudotype viruses: PV supernatant in a range of sucrose-PBS[4] 
concentrations was lyophilised (Labconco Freezone 2.5) overnight at final conditions of 
-50°C and <0.133mBar before being reconstituted and PV infectivity in relative 
luminescent units per ml (RLU/ml) calculated. 
 
Durability of lyophilised pseudotypes: Lyophilised PVs in the presence of 1M, 0.5M or 
no sucrose-PBS cryoprotectant were stored for 4 weeks at -80°C, -20°C, +4°C, +20°C and 
37°C (70% and 95% relative humidities) prior to reconstitution and RLU/ml calculation.  
 
Neutralisation of reconstituted pseudotypes (Figure 4) 
Reconstituted H5 and rabies PVs were compared to unlyophilised PV supernatant when  
employed in PVNAs against confirmed virus neutralising antibody (VNAb)-positive sera: 
• H5 – chicken sera post Volvac® AI KV H5N2 vaccination (Boehringer Ingelheim) 
• RABV – human sera post Rabipur® vaccination (Novartis) 
Serum serial dilutions were incubated with 1x106 RLUs of PV for 1hr at 37 °C before 
addition of 1x104 target cells – HEK293T/17 for H5 PVNAs or BHK-21 for RABV PVNAs - 
to each well of a 96-well culture plate, incubation for 48hrs and RLU measurement 
(Bright Glo reagent/Glomax 96 luminometer, Promega). IC50 and IC90 values (reciprocal 
of highest serum dilution that confers 50% and 90% neutralisation respectively) were 
















CONCLUSIONS & FURTHER CONSIDERATIONS 
• Lyophilised PVs (in 0.5M Sucrose-PBS) are stable after 4weeks’ incubation at up to 37°C, 
retain infectivity following reconstitution and can be as efficiently neutralised as fresh 
PV supernatant, confirming the viability of a PVNA-based kit for global distribution  
• Further considerations: 
• Extrapolate data by storage-testing of PV pellets for longer durations 
• Assess sensitivity of other pseudotype cores e.g. MLV, VSV, EIAV 
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Figure 2: Lyophilisation of  
lentiviral pseudotypes[6] 
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